Abstracts tagged "etanercept"

Abstract Number: 1516 • 2013 ACR/ARHP Annual Meeting
Safety and Efficacy Of Etanercept In Early Non-Radiographic Axial Spondyloarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial At 24 Weeks
Maxime Dougados¹, Désirée van der Heijde², Joachim Sieper³, Jürgen Braun⁴, Walter P. Maksymowych⁵, Gustavo Citera⁶, James Cheng-Chung Wei⁷, Jan Lenaerts⁸, Ronald Pedersen⁹, Randi Bonin¹⁰, Ehab Y. Mahgoub¹⁰, Bonnie Vlahos¹⁰ and Jack Bukowski¹¹, ¹Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Medicine, University of Alberta, Edmonton, AB, Canada, ⁶Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁷Institute of Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, ⁸Reuma Instituut, Hasselt, Belgium, ⁹Specialty Care, Pfizer Inc, Collegeville, PA, ¹⁰Pfizer Inc, Collegeville, PA, ¹¹Department of Specialty Care, Pfizer Inc, Collegeville, PA
Background/Purpose: Limited data are available on the efficacy of anti-TNF agents in non-radiographic axial spondyloarthritis (nr-axSpA). The objective of this analysis is to compare the…
Abstract Number: 2838 • 2013 ACR/ARHP Annual Meeting
Relationship Between Active Inflammatory Lesions In The Spine and Sacroiliac Joints and Development Of Fatty Lesions On Whole-Body MRI In Patients With Early Axial Spondyloarthritis- Long-Term Data Of The Esther Trial
In-Ho Song¹, Kay-Geert A. Hermann², Hildrun Haibel³, Christian Althoff⁴, Denis Poddubnyy³, Joachim Listing⁵, Anja Weiss⁶, Ekkehard Lange⁷, Bruce Freundlich⁸, Martin Rudwaleit⁹ and Joachim Sieper¹⁰, ¹Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ²Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Radiology, Charite Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ⁵German Rheumatism Research Center, Berlin, Germany, ⁶German Rheumatism Research Centre, Berlin, Germany, ⁷BU Specialty Care, Pfizer Pharma AG, Berlin, Germany, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Endokrinologikum, Berlin, Germany, ¹⁰Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin-Franklin, Berlin, Germany
Background/Purpose : In patients with early axial spondyloarthritis (SpA) with evidence of active inflammation on magnetic resonance imaging (MRI) in the spine and/or sacroiliac (SI-)joints…
Abstract Number: 1464 • 2013 ACR/ARHP Annual Meeting
Clinical and Radiographic Outcomes With Etanercept and Etanercept and Methotrexate In Patients With Rheumatoid Arthritis: Two-Year Results From The Canadian Methotrexate and Etanercept Outcome Study (CAMEO)
Boulos Haraoui¹, J. Carter Thorne², Edward C. Keystone³, Melanie Poulin-Costello⁴, Eric Trottier⁵, Andrew Vieira⁶ and Janet E. Pope⁷, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ⁴Biostatistics, Amgen Canada Inc., Mississauga, ON, Canada, ⁵Medical Communications, Amgen Canada, Mississauga, ON, Canada, ⁶Amgen Canada Inc., Mississauga, ON, Canada, ⁷St Joseph Health Care, London, ON, Canada
Background/Purpose: Data from the CAMEO study demonstrated that patients with rheumatoid arthritis (RA) who achieved low disease activity (LDA) after 6 months of combination therapy…
Abstract Number: 2678 • 2013 ACR/ARHP Annual Meeting
Medically Significant Infections Are Increased In Patients With Juvenile Idiopathic Arthritis Treated With Etanercept. Results From The British Society For Paediatric and Adolescent Rheumatology Etanercept Cohort Study
Rebecca Davies¹, Taunton R. Southwood², Lianne Kearsley-Fleet¹, Mark Lunt³, Kimme L. Hyrich⁴ and on Behalf Of The BSPAR Etanercept Cohort Study⁵, ¹Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ²Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ⁴Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom
Background/Purpose: The association between anti-TNF therapy and increased rate of infection are widely documented in adults with rheumatoid arthritis. Findings in children with juvenile idiopathic…
Abstract Number: 1446 • 2013 ACR/ARHP Annual Meeting
The Efficacy Of Etanercept In Combination With Methotrexate In Moderate To Severe Rheumatoid Arthritis Is Not Dependent On The Dosage Of Methotrexate
T.W.J. Huizinga¹, Fiona Brock², Urs Kerkmann³ and Gaia Gallo³, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Quanticate, Hitchin, Hertfordshire, United Kingdom, ³Pfizer Europe, Rome, Italy
Background/Purpose: Anti-TNF therapy in combination with a synthetic DMARD such as methotrexate (MTX) has been extensively shown to be superior to MTX and anti-TNF therapy…
Abstract Number: 2484 • 2013 ACR/ARHP Annual Meeting
Immunogenicity Of TNFα Blockers In Patients With Psoriatic Arthritis
Michael Zisapel Zisapel¹, Noa Madar-Balakirsi², Hagit Padova³, Irena Wigler⁴, Daphna Paran⁵, Uri Arad⁴, Dan Caspi⁶ and Ori Elkayam⁷, ¹Rheumatology, Tel Aviv Medical Centet, Tel Aviv, Israel, ²Rheumatology, Tel Aviv Medical Center, Tel Aviv, Israel, ³Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁴Department of Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁵Rheumatology, Tel Aviv Sourasky Medical Ctr, Tel-Aviv university, Tel Aviv, Israel, ⁶Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁷Rheumatology, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel- Aviv, Israel
Background/Purpose: TNFα blockers have been shown to produce immunogenecity in patients with rheumatoid arthritis, spondyloarthrritis and inflammatory bowel diseases. Data on the induction of anti-drug…
Abstract Number: 1449 • 2013 ACR/ARHP Annual Meeting
Comparison Of Effects Of Standard- and Low-Dose Etanercept On Inflammatory Synovitis In Rheumatoid Arthritis Patients As Assessed By Ultrasonography
Kenji Mamoto¹, Tatsuya Koike², Tadashi Okano¹, Yuko Sugioka¹, Masahiro Tada¹, Kentaro Inui³ and Hiroaki Nakamura¹, ¹Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Rheumatosurgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ³Orhtopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
Background/Purpose: The presence of synovitis has been recognized as one of the most important predictive factors of subsequent structural damage in patients with rheumatoid arthritis…
Abstract Number: 2379 • 2013 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis Patients With Stable Low Disease Activity On Methotrexate Plus Etanercept, Continuation Of Etanercept Is Superior Both Clinically and Radiographically To Discontinuation: Results From a Randomized, 3-Armed, Double-Blind Clinical Trial
Mikkel Østergaard¹, Marjatta Leirisalo-Repo², Till Uhlig³, Marita Jansson⁴, Esbjörn Larsson⁴, Fiona Brock⁵ and Ronald F. van Vollenhoven⁶, ¹Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ²Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴Pfizer AB, Sollentuna, Sweden, ⁵Quanticate, Hitchin, Hertfordshire, United Kingdom, ⁶Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden
Background/Purpose: The randomized clinical trial “DOSERA” has shown that in patients receiving concomitant methotrexate (MTX) therapy, continuation of etanercept (ETN) at 50 mg wkly is…
Abstract Number: 1423 • 2013 ACR/ARHP Annual Meeting
The Influence Of Body Mass Index On The Efficacy Of Tumor Necrosis Factor Blocking Therapy For Rheumatoid Arthritis
Ingrid M. Visman¹, Inge A.M. van den Oever¹, Charlotte L. M. Krieckaert¹, Gertjan Wolbink¹ and Michael T. Nurmohamed², ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²VU University Medical Center & Jan van Breemen Research Institute, Amsterdam, Netherlands
Background/Purpose : The impact of Body mass Index (BMI) on efficacy of TNF blocking therapy is an important question, as adipose tissue appears to have…
Abstract Number: 2359 • 2013 ACR/ARHP Annual Meeting
Impact Of Etanercept-Methotrexate Treatment Withdrawal On Patient-Reported Outcomes In Patients With Early Rheumatoid Arthritis (PRIZE Trial)
Piotr Wiland¹, B Combe², Oliver FitzGerald³, Hasan Tahir⁴, Stefanie Gaylord⁵, Theresa Williams⁵, Ronald Pedersen⁶, Jack Bukowski⁷, Bonnie Vlahos⁵ and Sameer Kotak⁸, ¹Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, ²Hôpital Lapeyronie, Montpellier, France, ³Department of Rheumatology, St.Vincent's University Hospital, Dublin, Ireland, ⁴Barts Health NHS Trust, London, United Kingdom, ⁵Department of Specialty Care, Pfizer Inc., Collegeville, PA, ⁶Specialty Care, Pfizer Inc, Collegeville, PA, ⁷Department of Specialty Care, Pfizer Inc, Collegeville, PA, ⁸Specialty Care, Pfizer Inc., New York, NY
Background/Purpose: Active rheumatoid arthritis (RA) is commonly associated with impairment of physical function and health-related quality of life (QoL), as well as work disability. The…
Abstract Number: 1359 • 2013 ACR/ARHP Annual Meeting
Does Rheumatoid Arthritis Disease Activity Correlate With Weather Conditions?
Eimear Savage¹, David McCormick¹, Stephen McDonald¹, Michael Stevenson², Owen Moore³ and Andrew Cairns⁴, ¹Rheumatology, Belfast Hospitals Trust, Musgrave Park Hospital, Belfast BT9 7JB, Northern Ireland, ²Medical Statistics, Centre for Public Health., Queens University, Belfast. School of Medicine, Dentistry and Biomedical Sciences., Belfast BT12 6BJ, Northern Ireland, ³Rheumatology, St. Vincent’s Hospital, Melbourne, Australia, ⁴Rheumatology, Belfast Hospitals Trust, Musgrave Park Hospital, Belfast, United Kingdom
Background/Purpose: Rheumatoid Arthritis is a common inflammatory joint condition affecting up to 1% of the Northern Ireland population. Patients often report increasing joint pain with…
Abstract Number: 2365 • 2013 ACR/ARHP Annual Meeting
Concomitant Methotrexate Did Not Affect Discontinuation Rate Of Etanercept Due To Ineffectiveness: Six-Year Results From Japanese Multicenter Registry System
Nobunori Takahashi¹, Toshihisa Kojima², Atsushi Kaneko³, Yuji Hirano⁴ and Naoki Ishiguro¹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, ³Orthopedic Surgery, Nagoya Medical Center, Nagoya, Japan, ⁴Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan
Background/Purpose: In the last decade, treatment with tumor necrosis factor (TNF) inhibitors has significantly improved the outcome in patients with rheumatoid arthritis (RA). Recent studies…
Abstract Number: 795 • 2013 ACR/ARHP Annual Meeting
Second TNF-Inhibitor Or Alternative Biologic In Juvenile Idiopathic Arthritis (JIA) Patients Failing a First TNF-Inhibitor
Kirsten Minden¹, Klaus Tenbrock², Gerd Horneff³ and Hans-Iko Huppertz⁴, ¹Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, ²University Aachen, Aachen, Germany, ³Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁴Prof. Hess Childrens Hospital, Bremen, Germany
Background/Purpose: Patients with incomplete response to initial anti-TNF treatment often are switched to other biologic treatments. However, little is known about the efficacy of switching…
Abstract Number: 2318 • 2013 ACR/ARHP Annual Meeting
Disease Activity in Moderate and Severe Rheumatoid Arthritis At Discontinuation in 10-Year Open-Label Extension Studies With Etanercept
Michael E. Weinblatt¹, Joan M. Bathon², Michele Hooper³, Bojena Bitman⁴, Yue Yang⁵, David H. Collier⁶, James Chung⁷ and Mark C. Genovese⁸, ¹Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Columbia University, New York, NY, ³Amgen Global Safety, Amgen Inc., Thousand Oaks, CA, ⁴Amgen, Inc., San Francisco, CA, ⁵Assent Consulting, South San Francisco, CA, ⁶Amgen Inc., Thousand Oaks, CA, ⁷Amgen, Thousand Oaks, CA, ⁸Division of Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Retention rates may be used as a surrogate of long-term effectiveness of drug therapy in open-label studies. Studies have reported that patients (pts)…
Abstract Number: 493 • 2013 ACR/ARHP Annual Meeting
A Real-World Risk Analysis Of Biological Treatment (Adalimumab and Etanercep) In Country With High Prevalence Of Tuberculosis and Hepatitis B/C
Ying-Ming Chiu¹, Chao-Hsiung Tang², Sheng-Tzu Hung³, Ya-Wen Yang⁴, Chi-Hui Fang⁴ and Hsiao-Yi Lin⁵, ¹Changhua Christian Hospital, Changhua City, Taiwan, ²Taipei Medical University, Taipei, Taiwan, ³Formosa Biomedical Technology Corp., Taipei, Taiwan, ⁴Pfizer Limited, Taipei, Taiwan, ⁵Immunology and Rheumatology, Dept of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
Background/Purpose: Biologics have been widely utilized in many rheumatic diseases. Risks associated with the use of biological treatments are revealed in many published studies. Nevertheless,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].